Literature DB >> 32238007

Dietary Intakes of Trace Elements and the Risk of Kidney Cancer: The Singapore Chinese Health Study.

Yeli Wang1, Tazeen H Jafar1,2, Aizhen Jin1, Jian-Min Yuan3,4, Woon-Puay Koh1,5.   

Abstract

Background: Epidemiological studies have demonstrated separately that patients with kidney stone may have higher dietary intake of zinc and higher risk of developing kidney cancer. We prospectively assessed the associations of dietary zinc and other trace elements with kidney cancer risk for the first time.
Methods: We used data from the prospective Singapore Chinese Health Study that recruited 63,257 adult Chinese residing in Singapore between 1993 and 1998. A validated food frequency questionnaire and the Singapore Food Composition Database was used to compute the values of intake for zinc, copper and manganese. We identified incident cancer cases via linkage with nationwide cancer registry, and used Cox proportional hazard models to compute hazard ratio (HR) and 95% confidence interval (CI) for the association with kidney cancer risk.
Results: There were 229 incident kidney cancer cases after median follow-up of 20.1 years. Dietary zinc intake was positively associated with higher kidney cancer risk; the HR comparing the extreme quartiles of zinc intake was 1.74 (95% CI: 1.02-2.97; P-trend = 0.033). Conversely, intakes of copper and manganese were not associated with kidney cancer risk.Conclusions: The positive association between dietary zinc and risk of kidney cancer suggests that zinc may be implicated in renal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32238007      PMCID: PMC7529837          DOI: 10.1080/01635581.2020.1743870

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  1 in total

1.  The Diagnostic Value of Serum Ang, VEGF, and CRP Combined with the Chinese Medicine Antitumor Formula in the Treatment of Advanced Renal Carcinoma.

Authors:  Nana Dong; Shengmin Zhang; Shuangjun Zhang; Qiongqiong Zhao; Donghua Zhang; Feng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-14       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.